ES2927352T8 - Inhibidores selectivos de HDAC6, método de preparación de los mismos y aplicación de los mismos - Google Patents
Inhibidores selectivos de HDAC6, método de preparación de los mismos y aplicación de los mismosInfo
- Publication number
- ES2927352T8 ES2927352T8 ES18739134T ES18739134T ES2927352T8 ES 2927352 T8 ES2927352 T8 ES 2927352T8 ES 18739134 T ES18739134 T ES 18739134T ES 18739134 T ES18739134 T ES 18739134T ES 2927352 T8 ES2927352 T8 ES 2927352T8
- Authority
- ES
- Spain
- Prior art keywords
- preparation
- application
- selective inhibitors
- hdac6 selective
- hdac6
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100022537 Histone deacetylase 6 Human genes 0.000 title 1
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 title 1
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/06—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710017287 | 2017-01-10 | ||
| PCT/CN2018/072088 WO2018130155A1 (zh) | 2017-01-10 | 2018-01-10 | Hdac6选择性抑制剂及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2927352T3 ES2927352T3 (es) | 2022-11-04 |
| ES2927352T8 true ES2927352T8 (es) | 2022-11-18 |
Family
ID=62839715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18739134T Active ES2927352T3 (es) | 2017-01-10 | 2018-01-10 | Inhibidores selectivos de HDAC6, método de preparación de los mismos y aplicación de los mismos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10745389B2 (es) |
| EP (1) | EP3569592B8 (es) |
| JP (1) | JP7237010B2 (es) |
| KR (1) | KR102549606B1 (es) |
| CN (1) | CN110382463B (es) |
| AU (1) | AU2018208160B2 (es) |
| ES (1) | ES2927352T3 (es) |
| IL (1) | IL267968B (es) |
| MX (1) | MX394624B (es) |
| SA (1) | SA519402090B1 (es) |
| SG (1) | SG11201906361YA (es) |
| WO (1) | WO2018130155A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2961765T3 (es) * | 2018-07-04 | 2024-03-13 | Cstone Pharmaceuticals Suzhou Co Ltd | Polimorfo del inhibidor selectivo de HDAC6 y su aplicación |
| JP2022538284A (ja) | 2019-06-27 | 2022-09-01 | ザ ジョージ ワシントン ユニバーシティ， ア コングレッショナリー チャータード ノット－フォー－プロフィット コーポレイション | Ｈｄａｃ６活性化マクロファージ、その組成物および使用 |
| WO2021110121A1 (zh) * | 2019-12-05 | 2021-06-10 | 基石药业（苏州）有限公司 | Hdac6选择性抑制剂及其组合疗法 |
| MX2022007376A (es) | 2019-12-20 | 2022-09-02 | Tenaya Therapeutics Inc | Fluoroalqull-oxadiazoles y sus usos. |
| IL307883A (en) | 2021-04-23 | 2023-12-01 | Tenaya Therapeutics Inc | HDAC6 inhibitors for use in the treatment of dilated myocardial disease |
| US20240252502A1 (en) | 2021-05-04 | 2024-08-01 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for treatment of metabolic disease and hfpef |
| WO2024123700A1 (en) * | 2022-12-05 | 2024-06-13 | The General Hospital Corporation | Histone deacetylase inhibitors |
| WO2025215092A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003209060A1 (en) * | 2002-02-07 | 2003-09-02 | Axys Pharmaceuticals, Inc. | Assay for acytyltransferase or deacetylase activity |
| CN101641338A (zh) | 2006-09-11 | 2010-02-03 | 柯瑞斯公司 | 作为抗增殖制剂的多功能小分子 |
| CN102123987A (zh) * | 2008-07-28 | 2011-07-13 | 吉里德科学公司 | 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物 |
| WO2011106632A1 (en) * | 2010-02-26 | 2011-09-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| NZ610225A (en) * | 2010-11-16 | 2015-08-28 | Acetylon Pharmaceuticals Inc | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
| US8404738B2 (en) * | 2011-01-21 | 2013-03-26 | Hoffmann-La Roche Inc. | 4-amino-N-hydroxy-benzamides for the treatment of cancer |
| EP2826769A1 (en) * | 2013-07-18 | 2015-01-21 | Institut de Recherche pour le Développement ( IRD) | Compounds for the treatment and/or prevention of parasitic diseases and method of production thereof |
| CA2933907A1 (en) | 2013-12-23 | 2015-07-02 | The Trustees Of Columbia University In The City Of New York | Selective hdac6 inhibitors |
| US9464073B2 (en) * | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
-
2018
- 2018-01-10 JP JP2019557669A patent/JP7237010B2/ja active Active
- 2018-01-10 MX MX2019008181A patent/MX394624B/es unknown
- 2018-01-10 EP EP18739134.7A patent/EP3569592B8/en active Active
- 2018-01-10 ES ES18739134T patent/ES2927352T3/es active Active
- 2018-01-10 KR KR1020197022672A patent/KR102549606B1/ko active Active
- 2018-01-10 CN CN201880006463.5A patent/CN110382463B/zh active Active
- 2018-01-10 US US16/476,660 patent/US10745389B2/en active Active
- 2018-01-10 SG SG11201906361YA patent/SG11201906361YA/en unknown
- 2018-01-10 AU AU2018208160A patent/AU2018208160B2/en active Active
- 2018-01-10 WO PCT/CN2018/072088 patent/WO2018130155A1/zh not_active Ceased
-
2019
- 2019-07-09 SA SA519402090A patent/SA519402090B1/ar unknown
- 2019-07-10 IL IL267968A patent/IL267968B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SA519402090B1 (ar) | 2022-05-30 |
| SG11201906361YA (en) | 2019-08-27 |
| US20190375735A1 (en) | 2019-12-12 |
| JP7237010B2 (ja) | 2023-03-10 |
| EP3569592B8 (en) | 2022-11-30 |
| IL267968B (en) | 2022-06-01 |
| EP3569592A4 (en) | 2020-08-12 |
| KR102549606B1 (ko) | 2023-06-29 |
| MX2019008181A (es) | 2019-12-09 |
| AU2018208160B2 (en) | 2021-03-04 |
| RU2019124962A3 (es) | 2021-05-11 |
| JP2020505440A (ja) | 2020-02-20 |
| CN110382463A (zh) | 2019-10-25 |
| EP3569592B1 (en) | 2022-08-24 |
| IL267968A (en) | 2019-10-31 |
| KR20190103286A (ko) | 2019-09-04 |
| RU2019124962A (ru) | 2021-02-15 |
| WO2018130155A1 (zh) | 2018-07-19 |
| BR112019014152A2 (pt) | 2020-03-31 |
| CN110382463B (zh) | 2022-11-04 |
| ES2927352T3 (es) | 2022-11-04 |
| MX394624B (es) | 2025-03-24 |
| AU2018208160A1 (en) | 2019-08-15 |
| CA3049834A1 (en) | 2018-07-19 |
| EP3569592A1 (en) | 2019-11-20 |
| US10745389B2 (en) | 2020-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272089B1 (en) | Compounds, compositions and methods | |
| EP3694181A4 (en) | SESSION ESTABLISHMENT PROCESS, DEVICE AND SYSTEM | |
| IL268955B (en) | Selective hdac6 inhibitors | |
| IL268684A (en) | Compositions and methods for immunooncology | |
| ES2927352T8 (es) | Inhibidores selectivos de HDAC6, método de preparación de los mismos y aplicación de los mismos | |
| IL268815A (en) | Compositions and methods for tumor transduction | |
| EP3672199A4 (en) | SYSTEM, APPARATUS AND METHOD FOR DEPLOYING APPLICATIONS | |
| EP3576036A4 (en) | SERVICE EXECUTION DEVICE AND METHOD | |
| BR112016027464A2 (pt) | aparelho de rede, e método de rede | |
| DK3170842T3 (da) | Immunologisk effektorcelle af målrettet cld18a2, fremstillingsfremgangsmåde og anvendelse deraf | |
| EP3600582A4 (en) | Mission-based, game-implemented cyber training system and method | |
| IL262824A (en) | Method, array and use thereof | |
| IT201700031317A1 (it) | Apparato e metodo di formatura di una imbottitura assorbente. | |
| EP3654568A4 (en) | SYNCHRONIZATION METHOD AND APPARATUS | |
| IL258956A (en) | Compositions and methods for tumor transduction | |
| BR112016025864A2 (pt) | método de lançamento do aplicativo de terminal e terminal | |
| PL3439975T3 (pl) | Rękaw opakowaniowy, opakowanie i sposób wytwarzania opakowania | |
| IL272924B1 (en) | Methods for making and using endoxifen | |
| IL256833A (en) | Il-17f-specific capture agents, compositions, and methods of using and making | |
| PT3265123T (pt) | Anticorpos, usos e métodos | |
| EP3902183C0 (en) | DEVICE AND METHOD FOR CONFIGURING RESOURCES | |
| EP3395366C0 (en) | METHOD FOR DESIGNING A DRUG, DRUG OBTAINED AND ASSOCIATED APPLICATION | |
| EP3706068A4 (en) | LAND USE DETERMINATION SYSTEM, LAND USE DETERMINATION METHOD AND PROGRAM | |
| PL3544347T3 (pl) | Sposób przesyłania informacji, urządzenie sieciowe i urządzenie końcowe | |
| DK3971177T3 (da) | Aminopyridin-derivater og anvendelse deraf som selektive ALK-2-inhibitorer |